Naibec Receives Approval for Phase 1 Clinical Trial Plan of Pulmonary Fibrosis Treatment in Australia
[Asia Economy Reporter Lee Jung-yoon] Nivek announced on the 22nd that the Phase 1 clinical trial plan for its peptide-based pulmonary fibrosis treatment (NIPEP-PF, clinical trial code NP-201) in Australia has been approved.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- AI Unlocks Virus Assembly Principles: Development of 'Protein Nanocages' for Vaccine Delivery [Reading Science]
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "After completing Phase 1 in Australia, depending on the evaluation results of pharmacokinetic characteristics, safety, tolerability, and immunogenicity observed during this clinical process, we plan to proceed to the next phase of patient-targeted clinical trials."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
